ANIXA BIOSCIENCES, INC. Deferred Federal Income Tax Expense (Benefit)
ANIXA BIOSCIENCES, INC. (ANIX) reported Deferred Federal Income Tax Expense (Benefit) of -$1.24 million for the 12-month period ending 2025-10-31, per its 10-K filed 2026-01-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-01-12
- ANIXA BIOSCIENCES, INC. deferred federal income tax expense (benefit) for fiscal 2025 was -$1.24M.
- ANIXA BIOSCIENCES, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$2.28M.
- ANIXA BIOSCIENCES, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$739.00M.
- ANIXA BIOSCIENCES, INC. deferred federal income tax expense (benefit) for fiscal 2022 was -$1.02B, a 169139.74% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-10-31 | -$1.24M 10-K · filed 2026-01-12 | |
| 2024-10-31 | -$2.28M 10-K · filed 2026-01-12 | -$2.28B 10-K · filed 2025-01-10 |
| 2023-10-31 | -$739.00M 10-K · filed 2025-01-10 | -$1.74B 10-K · filed 2024-01-16 |
| 2022-10-31 | -$1.02B 10-K · filed 2024-01-16 | -$1.02M 10-K · filed 2023-01-04 |
| 2021-10-31 | $604.00K 10-K · filed 2023-01-04 | |
| 2020-10-31 | $404.00K 10-K · filed 2022-01-04 | |
| 2019-10-31 | -$948.00K 10-K · filed 2021-01-07 | |
| 2018-10-31 | -$1.78M 10-K · filed 2020-01-09 | |
| 2017-10-31 | $12.53M 10-K · filed 2019-01-11 | -$12.53M 10-K · filed 2018-01-09 |
| 2016-10-31 | -$1.63M 10-K · filed 2018-01-09 | |
| 2015-10-31 | -$487.00K 10-K · filed 2016-12-08 | |
| 2014-10-31 | -$1.61M 10-K · filed 2015-12-23 | |
| 2013-10-31 | -$2.49M 10-K · filed 2015-01-29 | |
| 2012-10-31 | $992.00K 10-K/A · filed 2014-01-17 | |
| 2011-10-31 | $5.65M 10-K · filed 2013-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |